"Generare estimates that approximately 97% of the molecular chemistry encoded in microbial genomes remains uncharacterised. This presents a significant opportunity for drug discovery, as these molecules have historically been a foundational source of medicinal compounds."
"The company's platform utilizes high-throughput cloning and sequencing technology, validated through ERC-funded academic research, to screen tens of thousands of microbial genomes and identify gene sequences likely to produce bioactive molecules."
Generare, a Paris-based techbio company, has raised €20 million in a Series A funding round co-led by Alven and Daphni. The company focuses on screening microbial genomes to discover novel small molecules, claiming to have characterized more in 2025 than the rest of the field combined. Founded by Guillaume Vandenesch and Dr. Vincent Libis, Generare aims to unlock the 97% of molecular chemistry in microbial genomes that remains uncharacterized, using advanced cloning and sequencing technologies.
Read at TNW | Health-Tech
Unable to calculate read time
Collection
[
|
...
]